All News
Filter News
Found 809,030 articles
-
FSD Pharma Announces Strategic Business Developments
2/7/2019
FSD Pharma Inc. announced that its Board of Directors has concluded a strategic assessment of the Company and has implemented changes in leadership and business practices to optimize operations.
-
HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics
2/7/2019
HiberCell will build on pioneering tumor dormancy research conducted by the Julio Aguirre-Ghiso Lab at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
-
Centene Corporation Announces Two-For-One Stock Split Is Effective
2/7/2019
Centene Corporation announced that it has effected on February 6, 2019, a two-for-one stock split of its shares of common stock in the form of a 100% stock dividend distributed on February 6, 2019 to stockholders of record as of December 24, 2018.
-
Innovent Receives IND Approval of a Bispecific Antibody (IBI318) by the NMPA
2/7/2019
Innovent Biologics, Inc. announced that its IND application for IBI318 recently has been approved by the National Medical Products Administration to initiate clinical trials in patients with hematological and advanced solid tumors.
-
Taro Provides Results for December 31, 2018
2/7/2019
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the three and nine months ended December 31, 2018.
-
DelMar Pharmaceuticals Receives Nasdaq Listing Extension
2/7/2019
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new cancer therapies, announced that it has received a listing extension from the Nasdaq Hearings Panel.
-
EUREKA THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. HANZHONG LI AS SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT
2/7/2019
Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced the appointment of Hanzhong Li, Ph.D., M.B.A. as Senior Vice President of Corporate Development.
-
Apex Systems Wins ClearlyRated’s 2019 Best of Staffing® Client and Talent Awards
2/7/2019
Earned by less than two percent of all staffing agencies in the U.S. and Canada
-
AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
2/7/2019
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced two new appointments to its Executive Committee to accelerate the advancement of its multiple therapeutic candidates through preclinical and clinical development, thereby expanding and diversifying its pipeline.
-
Merck KGaA, Darmstadt, Germany and GlaxoSmithKline forged an agreement to develop an immunotherapy for difficult to treat cancers that could be worth up to $4 billion. Following the announcement, a subsidiary of Merck KGaA announced plans to expand its Billerica, Mass. R&D facility.
-
Trump’s SOTU Claim of Biggest Decline in Prescription Drug Prices Is for a One Month Period
2/6/2019
During the president’s annual address to Congress and the nation, Trump said that as a result of his administration’s efforts to lower the costs of prescription drugs, “in 2018 drug prices experienced their single largest decline in 46 years.” -
GlaxoSmithKline has been in the midst of a significant reshaping to focus on pharmaceuticals, particularly a renewed interest in oncology treatments. As a result, the company has made some cuts to its pipeline, including six quietly announced this morning in the company’s year-end report.
-
Robert Mahley, founder and president of Gladstone Institutes, an internationally-recognized expert on heart disease, cholesterol metabolism and Alzheimer’s disease, is launching a biotech company to focus on Alzheimer’s disease. The company is called GABAeron.
-
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
-
Like many other big pharma companies, Eli Lilly & Co. reported a good 2018 with a less optimistic view of 2019. Fourth-quarter 2018 revenue grew by 5 percent, driven by newer drugs. Operating expenses also went up by a percentage point. Full-year 2018 revenue grew by 7 percent to $24.556 billion.
-
Takeda Pharmaceutical released data from its Phase IIIb/IV clinical trial for Adynovate. On the same day, jurors in a Delaware federal court ordered Takeda’s Baxalta unit to pay $155.19 million to Bayer AG for infringing a patent for Adynovate.
-
Investors are not happy after Austin, Texas-based Pain Therapeutics announced that it was no closer to seeing its drug candidate Remoxy ER, an abuse-deterrent, extended-release gel formulation of oxycodone, approved by the U.S. Food and Drug Administration.
-
Notable will donate the commercial rights to price, manufacture, and distribute ND-1000 for pediatric leukemia to Cures Within Reach.
-
Shares of Rockville, Md.-based MacroGenics, Inc. have skyrocketed nearly 160 percent in premarket trading after the company announced its Phase III HER2-positive metastatic breast cancer study hit the mark.
-
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
2/6/2019
atalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications presented preclinical proof-of-concept data of CB 2679d-GT Factor IX gene therapy in hemophilia B mice.